Emorfazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H17N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V93U9DH62C, chemically known as 3(2h)-pyridazinone, 4-ethoxy-2-methyl-5-morpholino- but generally known as emorfazone, which bears US NIH Compound Identifier 3221. European Medicines Agency schedules Emorfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06511MIG. The term EMORFAZONE is an International Non-Proprietary Name. EMORFAZONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emorfazone under HS 29349990 and SITC 51579. As of Q4 2014, EMORFAZONE remains the US FDA Preferred Term for this commodity. Emorfazone bears US NLM identifiers UMLS ID C0059081 and NCI Concept Code C73085. SMILES: CCOC1=C(C=NN(C1=O)C)N2CCOCC2.